• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties

Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma

byAllen Ryu, BSandDeepti Shroff, DMD, MS
November 20, 2026
in All Specialties, Chronic Disease, Hematology, Pharma, Pulmonology
Reading Time: 4 mins read
Sickle cell anemia collage: round and sickle-shaped red blood cells, a wool scarf and a hot-water bottle
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized clinical trial of sickle cell disease (SCD) adult patients without asthma, use of inhaled mometasone was associated with increased soluble vascular cell adhesion molecule 1 (VCAM-1) levels, a marker of SCD severity.

2. Secondary outcomes, such as laboratory results, functional outcomes, patient-reported outcomes, and healthcare utilization, generally favored the placebo group, although results were not statistically significant.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Sickle cell disease (SCD) patients with episodic cough and wheeze (ECW) without asthma have high rates of pain episodes and acute chest syndrome (ACS). A previous study demonstrated that mometasone, an inhaled corticosteroid, improved daily pain and reduced vascular cell adhesion molecule 1 (VCAM-1) levels in patients with SCD and ECW without asthma. This study aimed to further examine potential efficacy of mometasone as a management and treatment option for SCD patients with ECW without asthma. Across 77 SCD (HbSS or HbSβ⁰) patients recruited between December 2018 and May 2022, soluble VCAM-1 levels increased by 42% in patients receiving mometasone compared to the placebo group, as well as 0.23% increase in intracellular adhesion molecule 3 (ICAM-3) levels. There were no significant differences in markers of hemolysis (plasma-free hemoglobin, lactate dehydrogenase, total bilirubin, reticulocyte count). Rates of healthcare service utilization (emergency department visits, acute visits for pain, hospital and intensive care unit admissions, and ACS) were higher in the mometasone group, although differences were not significant, either. A higher number of serious adverse events occurred in the mometasone group compared with the placebo group; eight episodes of ACS occurred in five individuals in the mometasone group, and four episodes of ACS occurred in three individuals in the placebo group. The single-center nature of the study limits its generalizability, and the small sample size decreases its statistical power. In addition, the study was not powered to detect differences in clinical outcomes. Lastly, spirometry and sputum collection were discontinued during the COVID-19 pandemic due to restrictions. Overall, the results of this study do not offer conclusive evidence on whether mometasone is effective for symptom management of SCD patients without asthma, and patients should use caution when considering mometasone.

Click here to read the study in JAMA Network Open

Relevant Reading: Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis

RELATED REPORTS

Less social media usage is associated with improved internalizing symptoms in high-risk young adults.

Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways

In-Depth [randomized controlled trial]: This study was a single-center, triple-blind , placebo-controlled, phase 2 randomized clinical trial. Participants were recruited from December 2018 to May 2022, with eligibility criteria being 18 years or older, had SCD (HbSS or HbSβ⁰), did not have asthma diagnosis or did not use asthma medications, were not currently experiencing pain/respiratory symptoms, reported ECW in the past 2 months, and were already taking maximum dose of hydroxyurea barring contraindication. Patients were ineligible if they were pregnant/planning a pregnancy, had more than 15 ED visits in the past year for SCD pain, discharged from a hospital in the past week, or screened positive for possible undiagnosed asthma. Once enrolled into the study, participants were randomly assigned to the treatment group (n=40) or the placebo group (n=37). The treatment group received 220 μg of inhaled mometasone furoate dry powder once daily; the placebo group received a matching placebo inhaler. Participants were followed up at weeks 0, 8, 16, 32, 40, 48, and 52; medications were started at week 0 and ended at week 48. At each visit, serum and sputum were collected, spirometry testing was administered, inhaled nitric oxide levels were measured, a Six-Minute Walk Test was completed, and patient-reported health-related quality of life data were collected. However, sputum collection and spirometry were halted during the COVID-19 pandemic. The primary endpoint was the VCAM-1 levels; participants in the treatment group had a 42% increase in VCAM-1 levels compared to placebo at the end of the study. Post hoc analysis showed no significant changes in VCAM-1 levels by week 8 (inhaled mometasone vs placebo: 0.001% [95% CI, −8.40% to 8.41%] vs −5.55% [95% CI, −16.48% to 5.37%]; p=0.40), but by week 16, soluble VCAM-1 levels had risen significantly in the inhaled mometasone group vs. the placebo group (3.6% [95% CI, −8.92% to 16.12%] vs −16.1% [95% CI, −27.25% to −4.97%]; p=0.02). Secondary endpoints included other markers of immune system activation/inflammation, hemolysis, organ damage, rates of healthcare service utilization, and rates of serious adverse events. ICAM-3, a marker of inflammation, showed an increase of  0.23% (95% CI, 0.019%-0.45%; p=0.02) in the mometasone group. Rates of healthcare utilization were higher across the board for the mometasone group, but results were not statistically significant (emergency department visit: rate ratio [RR], 1.59; 95% CI, 0.81-3.12; p=0.18, acute visits for pain: RR, 1.71; 95% CI, 0.64-4.56; p=0.28), hospital admissions (RR, 1.21; 95% CI, 0.52-2.81; p=0.65), intensive care unit admissions (RR, 2.18; 95% CI, 0.20-24.03; p=0.52), and ACS (RR, 4.27; 95% CI, 0.82-22.38; p=0.09). Higher numbers of adverse events occurred in the mometasone group (n=15) compared with the placebo group (n=11); eight episodes of ACS occurred in five individuals in the mometasone group, and four episodes of ACS occurred in three individuals in the placebo group. No deaths occurred during the study. Markers of hemolysis or organ damage were not significantly different between the groups. Overall, the results of this study suggested that 48 weeks of inhaled mometasone was not effective for symptom management of patients with SCD and episodic cough and wheeze without asthma.

Citation: Curtis SA, McCuskee S, Cohen RT, Liu A, Probst MA, Mitchell T, et al. Inhaled Corticosteroids and Sickle Cell Disease Severity in Adults Without Asthma: A Randomized Clinical Trial. JAMA Netw Open. 2026 Nov 2;9(11):e2642232. doi: 10.1001/jamanetworkopen.2026.42232. PMID: 43007675.

© 2026 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

Tags: adultsasthmacorticosteroidsdiseasesickle cell disease
Previous Post

Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer

RelatedReports

Teen smartphone use collage: a teenage boy in a hoodie looking down at a phone, with empty speech bubbles rising from it
All Specialties

Less social media usage is associated with improved internalizing symptoms in high-risk young adults.

November 19, 2026
A senior woman looks thoughtfully, accompanied by a DNA helix, a brain illustration, and cellular motifs, representing Alzheimer's genetic research.
Chronic Disease

Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways

November 15, 2026
Obesity measurement collage: a bathroom scale with a blank dial, a loose cloth measuring tape, an apple and a pear
Chronic Disease

Obesity associated with higher early-onset cancer risk among young Korean adults

November 13, 2026
A man walking along a path surrounded by healthy food options, sporting shoes, a heart illustration, and urban scenery, indicating lifestyle changes for cardiovascular health.
Cardiology

Elevated low-density lipoprotein cholesterol is a risk factor for atherosclerotic disease irrespective of familial hypercholesterolemia status

October 22, 2026
✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.